| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/18/2008 | US20080226640 Mixture comprising serum complement system protein (INSP162) use in preparation of vaccines and antibodies for treatment and prevention of infcetion, cell proliferative, skin, neurodegenerative, bone, inflammatory, respiratory system and autoimmune disorders |
| 09/18/2008 | US20080226639 Heparin Binding Peptide |
| 09/18/2008 | US20080226636 Novel human ulip/CRMP protein and use thereof in diagnosis and treatment of cancers and paraneoplastic neurological syndromes |
| 09/18/2008 | US20080226634 Tes7 and antibodies that bind thereto |
| 09/18/2008 | US20080226633 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 09/18/2008 | US20080226632 Cell growth factor specific immunoglobulin for treatment and prevention of cell proliferative and skin disorders |
| 09/18/2008 | US20080226624 Combined treatment of cancer by urokinase inhibition and a cytostatic anti-cancer agent for enhancing the anti-metastatic effect |
| 09/18/2008 | US20080226622 Hypoxia inducible factor (Hif); for modulating mRNA translation within cells; prevents excessive vascularization |
| 09/18/2008 | US20080226620 Polypeptide comprising major histocompatibility complex epitopes for use in targeting and destroying tumor cells |
| 09/18/2008 | US20080226617 Recombinant human arginase functioning as arginine depleting agent in treatment of cell proliferative disorders |
| 09/18/2008 | US20080226613 Using chronic inflammation as evaluative tool in predicting and detecting metastatic cancer |
| 09/18/2008 | US20080226610 Expression vector comprising nucleotide sequences coding syncytium-inducing polypeptide for use in targeting tumor cells for destruction; antitumor agents |
| 09/18/2008 | US20080226607 Polypeptide comprising major histocompatibility complex epitopes for use in targeting and destroying tumor cells |
| 09/18/2008 | US20080226606 Polypeptide comprising major histocompatibility complex epitopes for use in targeting and destroying tumor cells |
| 09/18/2008 | US20080226598 Dendritc specific RNA viral plasmid comprising nucleotide sequences coding tumor associated for use in developing cancer vaccine; genetic vaccines |
| 09/18/2008 | US20080226589 Compositions and methods of use of phorbol esters |
| 09/18/2008 | US20080226588 Treating melanoma with bis(thiohydrazide amides) |
| 09/18/2008 | US20080226583 Therapeutic polyesters and polyamides |
| 09/18/2008 | US20080226556 Using macrophages;milk fat globulins; epidermal growth factor mutants |
| 09/18/2008 | US20080226554 Polynucleotides encoding markers |
| 09/18/2008 | US20080226550 Mercaptan containing diagnostic agents for imaging malignant melanoma and distant metastases and rhenium (186Re, 188Re) therapeutic complexes for treating the same |
| 09/18/2008 | US20080226549 Diagnosing cancer; measuring antibody inhibition; calibration; reduced concentration of inhibitor indicates cancer receptivity |
| 09/18/2008 | US20080226547 Anticancer agents, antitumor agents |
| 09/18/2008 | US20080226546 Kit for preparation of nano-targeted liposome drug in combined radionuclide therapy and chemotherapy |
| 09/18/2008 | CA2703136A1 Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer |
| 09/18/2008 | CA2702650A1 Phenyl amino pyrimidine compounds and uses thereof |
| 09/18/2008 | CA2680914A1 Monoclonal human tumor-specific antibody |
| 09/18/2008 | CA2680759A1 Kunitz-type recombinant inhibitor |
| 09/18/2008 | CA2680625A1 Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors |
| 09/18/2008 | CA2680600A1 Li-rnai involved li suppression in cancer immunotherapy |
| 09/18/2008 | CA2680556A1 Biomarkers of prostate cancer and uses thereof |
| 09/18/2008 | CA2680481A1 Intravesical apaziquone administration following transurethral resection for treating cancer |
| 09/18/2008 | CA2680467A1 Inhibitors of histone deacetylase |
| 09/18/2008 | CA2680414A1 Piperidinones useful in the treatment of inflammation |
| 09/18/2008 | CA2680412A1 Piperidinones useful in the treatment of inflammation |
| 09/18/2008 | CA2680366A1 Inhibitors of carnitine palmitoyltransferase and treating cancer |
| 09/18/2008 | CA2680280A1 Remedy for chemotherapy-resistant cancer containing hla class i-recognizing antibody as the active ingredient and use of the same |
| 09/18/2008 | CA2680122A1 Pharmaceutical composition |
| 09/18/2008 | CA2679986A1 Epha3 antibodies for the treatment of solid tumors |
| 09/18/2008 | CA2679878A1 Pharmaceutical compounds |
| 09/18/2008 | CA2679643A1 Procaspase 8-mediated disease targeting |
| 09/18/2008 | CA2679589A1 Method for production of sugar oxazoline derivative |
| 09/18/2008 | CA2679497A1 Diagnostic and therapeutic aspects of sparc promoter hypermethylation in colon cancer |
| 09/18/2008 | CA2679268A1 Treatment of melanoma |
| 09/18/2008 | CA2679050A1 Cytotoxicity mediation of cells evidencing surface expression of cd44 |
| 09/18/2008 | CA2678732A1 Monoclonal antibodies for treatment of cancer |
| 09/18/2008 | CA2678721A1 Reoviruses having modified sequences |
| 09/18/2008 | CA2677874A1 Amide compounds and their use as antitumor agents |
| 09/17/2008 | EP1970449A1 Attenuated salmonella SPI2 mutants as antigen carriers |
| 09/17/2008 | EP1970385A2 Tetravalent anti-CD20 and/or anti-CD23 antibodies |
| 09/17/2008 | EP1970384A1 Monoclonal antibodies for treatment of cancer |
| 09/17/2008 | EP1970383A1 Compounds and methods for modulating nonclassical cadherin-mediated functions |
| 09/17/2008 | EP1970378A1 Photoreactive Ru (II) complexes anchored on oligonucleotides, method for obtaining them and use thereof |
| 09/17/2008 | EP1970075A1 THERAPEUTIC AGENT FOR NEUROBLASTOMA TARGETING ARID3b |
| 09/17/2008 | EP1970072A1 Use of GLP-2 peptides for the treatment of hyperparathyroidism |
| 09/17/2008 | EP1969951A2 Compositions against inflammatory processes |
| 09/17/2008 | EP1969000A2 Cell penetrating peptides for intracellular delivery of molecules |
| 09/17/2008 | EP1968984A1 Lestaurtinib crystalline form 1, crystalline lestaurimib anhydrate and amorphous lestaurimib |
| 09/17/2008 | EP1968981A2 A method of treating tumors with azaxanthones |
| 09/17/2008 | EP1968979A2 9-membered heterobicyclic compounds as inhibitors of protein kinases |
| 09/17/2008 | EP1968976A1 Substituted pyrazolo [4,3-c] pyridine derivatives active as kinase inhibitors |
| 09/17/2008 | EP1968975A2 Tylophorine analogs as antitumor agents |
| 09/17/2008 | EP1968950A1 Pyrimidine kinase inhibitors |
| 09/17/2008 | EP1968948A2 Novel hydrogen sulfate salt |
| 09/17/2008 | EP1968944A1 Alkylsulphonamide quinolines |
| 09/17/2008 | EP1968937A1 Deazapurine analogs of 1'-aza-l-nucleosides |
| 09/17/2008 | EP1968640A1 Compounds for use in treating abnormal cell proliferation, and methods of producing same |
| 09/17/2008 | EP1968633A1 Combination therapy using anti-egfr and anti-her2 antibodies |
| 09/17/2008 | EP1968616A2 Derivatives of sulindac, use thereof and preparation thereof |
| 09/17/2008 | EP1968609A2 Pharmaceutical compositions and methods of use of highly lipophilic sulfhydryl compounds |
| 09/17/2008 | EP1968607A1 Treatment of cancer and other diseases |
| 09/17/2008 | EP1968604A2 Crystalline lestaurtinib hydrates and crystalline lestaurtinib hemihydrate hemiacetonitrileate and crystalline lestaurtinib hemihydrate hemitetrahydrofuranate |
| 09/17/2008 | EP1968602A1 Treatment of barrett's esophagus |
| 09/17/2008 | EP1968595A2 Methods of treating cancer and other conditions or disease states using l-cytosine nucleoside analogs |
| 09/17/2008 | EP1968592A2 Formulations comprising jorumycin-, renieramycin-, safracin- or saframycin-related compounds for treating proliferative diseases |
| 09/17/2008 | EP1968589A2 Combinations comprising sorafenib and interferon for the treatment of cancer |
| 09/17/2008 | EP1968582A2 Treatment for cutaneous t cell lymphoma |
| 09/17/2008 | EP1968579A1 Pharmaceutical compounds |
| 09/17/2008 | EP1968576A1 Mif inhibitors |
| 09/17/2008 | EP1968568A2 INHIBITORS OF Akt ACTIVITY |
| 09/17/2008 | EP1968564A2 Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance in type 1 and type 2 cytokine production |
| 09/17/2008 | EP1968556A1 Composition, and use thereof, in respect if cancer, prophylactic treatment and infection in the urinary tract, involving nitric oxide |
| 09/17/2008 | EP1802274B1 Use of cannabidiol for the inhibition of brain tumour cell migration |
| 09/17/2008 | EP1638978A4 7-substituted camptothecin and camptothecin analogs and methods for preparing same |
| 09/17/2008 | EP1597239B1 Polymorph of {6,7-bis(2-methoxy-ethoxy)-quinazolin-4-yl}-(3e) |
| 09/17/2008 | EP1509543B1 Non-immunosuppressive imunogenic or vaccine composition comprising a mutated e7 protein of the hpv-16 virus |
| 09/17/2008 | EP1495003B1 Fredericamycin derivatives |
| 09/17/2008 | EP1463525B1 Compositions and methods for the diagnosis and treatment of tumor |
| 09/17/2008 | EP1379557B1 Use of cd25 binding molecules in steroid-resistant patients |
| 09/17/2008 | EP1307450B1 2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido(2,3-d)pyrimidin-7-ones |
| 09/17/2008 | EP1254122B1 Novel 3-substituted 1,2,4-benzotriazines, a method for their production and the use thereof |
| 09/17/2008 | EP1202748B1 Polycation-based bioconjugates |
| 09/17/2008 | EP1202736B1 Nicotine in therapeutic angiogenesis and vasculogenesis |
| 09/17/2008 | EP1141331B1 HUMAN CYCLIN-DEPENDENT KINASE (hPNQALRE) |
| 09/17/2008 | CN101268101A Anti-CTLA-4 antibody and CpG-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment |
| 09/17/2008 | CN101268095A Bifunctional protein anchors |
| 09/17/2008 | CN101268085A Boron compounds useful in BNCT |
| 09/17/2008 | CN101268070A Novel sulphonylpyrroles as inhibitors of HDAC novel sulphonylpyrroles |
| 09/17/2008 | CN101268048A Carbazole derivatives |
| 09/17/2008 | CN101267859A A pharmaceutical composition useful for the treatment of prostate cancer |